Beautem’s strategic focus is defined by three key pillars:
High purity
Achieved through a patented purification technology that minimizes impurities.
Optimized clinical performance
Characterized by a fast onset of action and stable efficacy in the treatment of dynamic wrinkles.
Strong scientific support
Backed by data from large-scale, global clinical studies.
Botulinum Toxin Type A, vacuum-dried powder for injection
Beautem is a high-purity botulinum toxin type A developed with a patented purification technology, designed to deliver consistent efficacy and a high level of safety in medical aesthetics. It is recognized as the first Asian botulinum toxin approved by the U.S. FDA, and has also received approval from the EMA and Health Canada, reinforcing its internationally recognized quality standards.
Product Role
Beautem is indicated for the temporary improvement of moderate to severe glabellar lines in adults, helping create a more relaxed and harmonious appearance. Developed on the prabotulinumtoxinA platform, the product is supported by large-scale international clinical data demonstrating both efficacy and safety in aesthetic treatment.
Key Features and Benefits
Beautem features a high-purity 900 kDa botulinum toxin complex, manufactured using Daewoong’s biotechnology platform and a patented purification process. The product has been evaluated in global studies involving more than 2,000 patients across the United States, Europe, and Canada, and has also been shown to be non-inferior to onabotulinumtoxinA in direct comparative studies.
Composition
Each vial of Beautem contains 100 units of Clostridium Botulinum Toxin Type A.
Indications
Beautem is indicated for the temporary improvement of moderate to severe vertical lines between the eyebrows that appear during frowning in adults aged 20 to 65 years.
Dosage and Administration
Beautem should be reconstituted with preservative-free sterile sodium chloride to yield a solution of 100 U/2.5 mL (4 U/0.1 mL). The recommended dose is 4 units per injection point across 5 injection sites—two in each corrugator muscle and one in the procerus muscle—for a total dose of 20 units.
The core strength of Beautem lies in its proprietary HiPURE Technology, which allows the extraction of botulinum toxin with exceptionally high purity. More than 98% of the formulation consists of the 900 kDa botulinum toxin complex, a critical factor in reducing impurities associated with treatment resistance and ensuring optimal product stability in aesthetic applications.
From a pharmacokinetic perspective, Beautem demonstrates a rapid onset of action, typically beginning within approximately 2 days. The safety and efficacy of this technology platform have been confirmed through clinical studies involving over 2,000 patients across the United States, Europe, and Canada.
Indication
Beautem is indicated for the temporary improvement of moderate to severe vertical glabellar lines associated with frowning in adult patients
Clinical Use Guidelines
- Reconstitution: Use sterile, preservativefree 0.9% sodium chloride solution.
- Recommended dose: For glabellar lines, the standard total dose is 20 units, administered across 5 injection points (4 units per point).
- Clinical response: Noticeable improvement is usually observed within about one week, with results lasting up to 4 months.
Beautem is intended for use only by physicians or trained medical professionals with appropriate expertise in injection techniques and facial anatomy.
Beautem is manufactured in facilities compliant with US cGMP and EU GMP standards, meeting stringent international pharmaceutical production requirements. Regulatory approvals from FDA, EMA, along with patented proprietary technologies, further validate the product’s clinical credibility.
Supported by controlled clinical data and international regulatory recognition, Beautem is positioned as a reliable botulinum toxin type A solution with a solid scientific foundation for modern aesthetic medicine.